DR Andre Spółka z Ograniczoną Odpowiedzialnością (KRS 0000720144, NIP 5542961129) is a Polish company, headquartered in Bydgoszcz, Kujawsko-Pomorskie voivodeship. DR ANDRE operates in: Manufacture of pharmaceutical preparations (PKD 21.20.Z). Industry: Pharmaceuticals. The company has been listed in the National Court Register since February 22, 2018. DR ANDRE's most recently reported net revenue was 1.2 M PLN for 2024.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - DR Andre
Identity
- Name
- DR Andre Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- February 22, 2018
- Registry status as of
- November 21, 2025
- Latest entry
- June 11, 2025
- Founding act
- 20.02.2018
Articles of association history (2)
- February 20, 2018: 20.02.2018
- August 20, 2018: 20.08.2018R. - ZMIANA UMOWY § 3
Activities
Main activity
21.20.ZManufacture of pharmaceutical preparations
Other activities
Address and contact
- Address
- UL. KIJOWSKA, 44, 85-703, BYDGOSZCZ, POLSKA
- Voivodeship
- KUJAWSKO-POMORSKIE
- District
- BYDGOSZCZ
- BIURO@DRANDRE.PL
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-84603-79921-SATJW-16
- Coordinates
- 53.1267, 18.0114approx.
Risk and payment profile - DR Andre
Credibility rating
65.4 / 100
Good credibility
Insolvency risk
Very low
Low threat
Closure risk
1
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
1
1/8 yrs
Board changes
1
1/8 yrs
PKD changes
0
0/8 yrs
Name changes
0
0/8 yrs
Data from 8 years of registry activity.
Credibility history
Payment reliability score from 2018–2024
Current: C (65/100)
Trend: improving (+19.5 pts/year)
Moderate payment credibility - the company is able to meet its obligations, but some indicators warrant caution.
Trade credit limit history
Standard limit from 2018–2024
Current: 49.6 K PLN
Safe: 22.3 K PLN
Difference between risk models
Closure - probability of ceasing operations (operational continuity). Insolvency - probability of formal bankruptcy / restructuring. The models use different data - results can diverge significantly when balance-sheet data is incomplete.
Operational status - DR Andre
Founded
February 22, 2018
8 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
BYDGOSZCZ
KUJAWSKO-POMORSKIE
Primary PKD
21.20.Z
Manufacture of pharmaceutical preparations
Share capital
5.0 K PLN
95 shares total
Shareholders
2
shareholders
Board
1 person
Filed years
7 years
2018–2024 · profitable: 3/7
Registry entries
20
latest: June 11, 2025
Revenue
1.2 M PLN
2024
Net profit
54.3 K PLN
2024
Assets
738.8 K PLN
2024
Equity
N/A
2024
EBITDA
119.3 K PLN
2024
Valuation
429.4 K PLN
Low confidence
Low confidence
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - DR Andre.
No ratings
Related articles
News
Bioton 2025: record EBITDA of PLN 53.8 m and revenue of PLN 235.9 m, but still a PLN 16.4 m net loss
Warsaw-based Bioton S.A. (KRS 0000214072) - the only Polish manufacturer of biosynthetic human insulin - closed 2025 with revenue of PLN 235.9 m and EBITDA of PLN 53.82 m (margin 18.72%), but a net loss of around PLN -16.4 m keeps the company in the red. EBITDA improved 76% versus 2024 (PLN 30.6 m), driven by international expansion (Malaysia ~PLN 100 m a year) and a contract to produce the insulin analogue Glargine. Yifan Pharmaceutical controls 31.65% of capital indirectly.
News
Celon Pharma 2025: record PLN 244 m revenue, but net loss deepens to PLN 79.4 m - the 2026 outlook hinges on Salmex registration in China and the GLP-1 programme
Celon Pharma S.A. (KRS 0000437778, Kiełpin/Łomianki) closed 2025 with consolidated revenue of PLN 244.34 m (+17.9% YoY), EBITDA of PLN 21.42 m (+42%) and a deepened net loss of PLN -79.36 m (vs PLN -34.45 m a year earlier). The deeper loss reflects spending on the innovative GLP-1 segment. The generics segment grows (+15.3%) and represents 84.4% of revenue. Salmex registration in China is expected by end-2026. Maciej Wieczorek controls 58.8% of capital and 68.2% of voting rights through Glatton sp. z o.o.
